Patents by Inventor Ryota Shiraki
Ryota Shiraki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9708307Abstract: A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: GrantFiled: October 28, 2014Date of Patent: July 18, 2017Assignee: Astellas Pharma Inc.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Publication number: 20150045402Abstract: A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: ApplicationFiled: October 28, 2014Publication date: February 12, 2015Applicant: ASTELLAS PHARMA INC.Inventors: Ryota Shiraki, Takahiko TOBE, Shimpei KAWAKAMI, Hiroyuki MORITOMO, Makoto OHMIYA
-
Patent number: 8937087Abstract: [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: GrantFiled: April 18, 2014Date of Patent: January 20, 2015Assignee: Astellas Pharma Inc.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Publication number: 20140315963Abstract: [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: ApplicationFiled: April 18, 2014Publication date: October 23, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Patent number: 8198464Abstract: The present invention provides a method for producing a C-glycoside derivative, which can produce the C-glycoside derivative at a high yield and at a low cost, which conforms to environmental protection, and which is applicable industrially. The C-glycoside derivative is useful for treating and preventing diabetes such as insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes) and the like and various diabetes-related diseases including insulin-resistant diseases and obesity.Type: GrantFiled: December 20, 2007Date of Patent: June 12, 2012Assignees: Astellas Pharma Inc., Kotobuki Pharmaceutical Co., Ltd.Inventors: Kousuke Komenoi, Atsushi Nakamura, Makoto Kasai, Masakazu Imamura, Ryota Shiraki, Keita Nakanishi
-
Patent number: 8097592Abstract: A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.Type: GrantFiled: April 4, 2007Date of Patent: January 17, 2012Assignees: Astellas Pharma Inc., Kotobuki Pharmaceutical Co. Ltd.Inventors: Masakazu Imamura, Keita Nakanishi, Ryota Shiraki, Kenichi Onda, Daisuke Sasuga, Masamichi Yuda
-
Patent number: 7977466Abstract: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.Type: GrantFiled: July 15, 2008Date of Patent: July 12, 2011Assignees: Astellas Pharma Inc., Kotobuki Pharmaceutical Co., Ltd.Inventors: Masakazu Imamura, Takeshi Murakami, Ryota Shiraki, Kazuhiro Ikegai, Takashi Sugane, Fumiyoshi Iwasaki, Eiji Kurosaki, Hiroshi Tomiyama, Atsushi Noda, Kayoko Kitta, Yoshinori Kobayashi
-
Patent number: 7776897Abstract: There is provided a compound which can be used for therapy of diseases in which 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) participates, in particular diabetes, insulin resistance. It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11?-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action and hence can be used for therapy of diabetes, insulin resistance.Type: GrantFiled: September 14, 2005Date of Patent: August 17, 2010Assignee: Astellas Pharma Inc.Inventors: Takeshi Murakami, Tomoaki Kawano, Ryota Shiraki, Hirofumi Ishii, Seiji Yoshimura, Takehiko Ohkawa, Mitsuru Hosaka, Hiroki Fukudome, Yutaka Inoki
-
Patent number: 7772407Abstract: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.Type: GrantFiled: February 26, 2007Date of Patent: August 10, 2010Assignees: Astellas Pharma Inc., Kotobuki Pharmaceuticals Co., Ltd.Inventors: Masakazu Imamura, Takeshi Murakami, Ryota Shiraki, Kazuhiro Ikegai, Takashi Sugane, Fumiyoshi Iwasaki, Eiji Kurosaki, Hiroshi Tomiyama, Atsushi Noda, Kayoko Kitta, Yoshinori Kobayashi
-
Publication number: 20100094025Abstract: The present invention provides a method for producing a C-glycoside derivative, which can produce the C-glycoside derivative at a high yield and at a low cost, which conforms to environmental protection, and which is applicable industrially. The C-glycoside derivative is useful for treating and preventing diabetes such as insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes) and the like and various diabetes-related diseases including insulin-resistant diseases and obesity.Type: ApplicationFiled: December 20, 2007Publication date: April 15, 2010Applicants: ASTELLAS PHARMA INC., KOTOBUKI PHARMACEUTICAL CO., LTD.Inventors: Kousuke Komenoi, Atsushi Nakamura, Makoto Kasai, Masakazu Imamura, Ryota Shiraki, Keita Nakanishi
-
Publication number: 20090143316Abstract: A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.Type: ApplicationFiled: April 4, 2007Publication date: June 4, 2009Applicants: ASTELLAS PHARMA INC., KOTOBUKI PHARMACEUTICAL CO., LTD.Inventors: Masakazu Imamura, Keita Nakanishi, Ryota Shiraki, Kenichi Onda, Daisuke Sasuga, Masamichi Yuda
-
Publication number: 20090082367Abstract: [Problem] To provide a compound which may be used in treating diseases in which 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) is concerned, especially diabetes and insulin resistance. [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11?-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.Type: ApplicationFiled: March 14, 2007Publication date: March 26, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Seiji Yoshimura, Ryota Shiraki, Tomoaki Kawano, Daisuke Sasuga, Mitsuru Hosaka, Hiroki Fukudome, Kazuo Kurosawa, Hirofumi Ishii, Takanori Koike
-
Publication number: 20090069252Abstract: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.Type: ApplicationFiled: July 15, 2008Publication date: March 12, 2009Applicants: Astellas Pharma Inc., Kotobuki Pharmaceutical Co., Ltd.Inventors: Masakazu Imamura, Takeshi Murakami, Ryota Shiraki, Kazuhiro Ikegai, Takashi Sugane, Fumiyoshi Iwasaki, Eiji Kurosaki, Hiroshi Tomiyama, Atsushi Noda, Kayoko Kitta, Yoshinori Kobayashi
-
Patent number: 7307074Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4?-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.Type: GrantFiled: September 8, 2003Date of Patent: December 11, 2007Assignee: Astellas Pharma Inc.Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe
-
Publication number: 20070259854Abstract: [Problem] There is provided a compound which can be used for therapy of diseases in which 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) participates, in particular diabetes, insulin resistance. [Means for Solution] It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11?-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action and hence can be used for therapy of diabetes, insulin resistance.Type: ApplicationFiled: September 14, 2005Publication date: November 8, 2007Applicant: ASTELLAS PHARMA INC.Inventors: Takeshi Murakami, Tomoaki Kawano, Ryota Shiraki, Hirofumi Ishii, Seiji Yoshimura, Takehiko Ohkawa, Mitsuru Hosaka, Hiroki Fukudome, Yutaka Inoki
-
Publication number: 20070161787Abstract: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.Type: ApplicationFiled: February 26, 2007Publication date: July 12, 2007Applicants: Astellas Pharma Inc., Kotobuki Pharmaceutical Co., Ltd.Inventors: Masakazu Imamura, Takeshi Murakami, Ryota Shiraki, Kazuhiro Ikegai, Takashi Sugane, Fumiyoshi Iwasaki, Eiji Kurosaki, Hiroshi Tomiyama, Atsushi Noda, Kayoko Kitta, Yoshinori Kobayashi
-
Patent number: 7202350Abstract: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.Type: GrantFiled: March 12, 2004Date of Patent: April 10, 2007Assignees: Astellas Pharma Inc., Kotobuki Pharmaceutical Co., LtdInventors: Masakazu Imamura, Takeshi Murakami, Ryota Shiraki, Kazuhiro Ikegai, Takashi Sugane, Fumiyoshi Iwasaki, Eiji Kurosaki, Hiroshi Tomiyama, Atsushi Noda, Kayoko Kitta, Yoshinori Kobayashi
-
Publication number: 20060122126Abstract: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.Type: ApplicationFiled: March 12, 2004Publication date: June 8, 2006Inventors: Masakazu Imamura, Takeshi Murakami, Ryota Shiraki, Kazuhiro Ikegai, Takashi Sugane, Fumiyoshi Iwasaki, Eiji Kurosaki, Hiroshi Tomiyama, Atsushi Noda, Kayoko Kitta, Yoshinori Kobayashi
-
Patent number: 6740662Abstract: 2-Oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by bearing a specific substituent, —X—R6, at the 3-position and a cyclic substituent, R5, at the 4-position; or salts thereof. The derivatives and the salts are useful as drugs, particularly preventive or therapeutic agents for respiratory diseases related to PDE IV.Type: GrantFiled: April 19, 2002Date of Patent: May 25, 2004Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Masahiro Iwata, Noriyuki Kawano, Tomofumi Takuwa, Ryota Shiraki, Miki Kobayashi, Makoto Takeuchi
-
Patent number: RE43481Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4?-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.Type: GrantFiled: September 3, 2008Date of Patent: June 19, 2012Assignee: Astellas Pharma Inc.Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe